Delivery Order SPE2DB25D3020-SPE2DB25FWKNE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic (0.25-0.5 mg/dose pen, 3ml formulation) with a ceiling value of $19,962.14. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a typical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $10,712.92 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) pre-filled pens on August 18, 2025, with completion expected by August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $9,153.24. This competitively awarded, firm fixed-price contract represents a single delivery order with an ultimate completion date of August 22, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency (DLA) awarded a $10,739.93 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ozempic 0.25–0.5 mg/dose pens (3 mL). This firm fixed-price delivery order is scheduled for completion by July 24, 2025, and will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the vendor's capability to meet federal procurement requirements through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) prefilled pens with a ceiling value of $15,728.80. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract involves no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,133.30 to supply Ozempic 0.25-0.5 mg/dose pens in 3 mL quantities, with an ultimate completion date of August 1, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a $4,713.64 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic (0.25-0.5 mg/dose pens, 3ml) on September 3, 2025, with ultimate completion scheduled for September 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $1,957.32. This competitive, firm fixed-price delivery order is set to be completed by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under a larger contract vehicle, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a $33,160.61 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL), with completion targeted for August 20, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where the vendor maintains its corporate office and...
- The Defense Logistics Agency awarded a delivery order valued at $17,574.08 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on September 9, 2025, with completion targeted for September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWKNEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) prefilled pens valued at $14,830.14. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and a completion date of September 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive global pharmaceutical prime vendor contract enables the company to supply a broad range of medications, medical devices, and healthcare commodities to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's federal procurement portfolio demonstrates consistent capability in fulfilling competitive pharmaceutical supply requirements across multiple therapeutic domains, including specialty medications and brand-name drugs essential to military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.8k | 9/10/25 |